{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:58:17Z","timestamp":1787500697568,"version":"build-2736575974"},"reference-count":34,"publisher":"The Journal of Rheumatology","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2018,4]]},"abstract":"<jats:sec>\n                    <jats:title>Objective.<\/jats:title>\n                    <jats:p>Around one-third of patients with juvenile idiopathic arthritis (JIA) fail to respond to first-line methotrexate (MTX) or anti-tumor necrosis factor (TNF) therapy, with even fewer achieving \u2265 American College of Rheumatology Pediatric 70% criteria for response (ACRpedi70), though individual responses cannot yet be accurately predicted. Because change in serum S100-protein myeloid-related protein complex 8\/14 (MRP8\/14) is associated with therapeutic response, we tested granulocyte-specific S100-protein S100A12 as a potential biomarker for treatment response.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>S100A12 serum concentration was determined by ELISA in patients treated with MTX (n = 75) and anti-TNF (n = 88) at baseline and followup. Treatment response (\u2265 ACRpedi50 score), achievement of inactive disease, and improvement in Juvenile Arthritis Disease Activity Score (JADAS)-10 score were recorded.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Baseline S100A12 concentration was measured in patients treated with anti-TNF [etanercept n = 81, adalimumab n = 7; median 200, interquartile range (IQR) 133\u2013440 ng\/ml] and MTX (median 220, IQR 100\u2013440 ng\/ml). Of the patients in the anti-TNF therapy group, 74 (84%) were also receiving MTX. Responders to MTX (n = 57\/75) and anti-TNF (n = 66\/88) therapy had higher baseline S100A12 concentration compared to nonresponders: median 240 (IQR 125\u2013615) ng\/ml versus 150 (IQR 87\u2013233) ng\/ml, p = 0.021 for MTX, and median 308 (IQR 150\u2013624) ng\/ml versus 151 (IQR 83\u2013201) ng\/ml, p = 0.002, for anti-TNF therapy. Followup S100A12 could be measured in 44\/75 MTX-treated patients (34\/44 responders) and 39\/88 anti-TNF-treated patients (26\/39 responders). Responders had significantly reduced S100A12 concentration (MTX: p = 0.031, anti-TNF: p &lt; 0.001) at followup versus baseline. Baseline serum S100A12 in both univariate and multivariate regression models for anti-TNF therapy and univariate analysis alone for MTX therapy was significantly associated with change in JADAS-10.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion.<\/jats:title>\n                    <jats:p>Responders to MTX or anti-TNF treatment can be identified by higher pretreatment S100A12 serum concentration levels.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3899\/jrheum.170438","type":"journal-article","created":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T20:10:14Z","timestamp":1516047014000},"page":"547-554","source":"Crossref","is-referenced-by-count":30,"title":["S100A12 Is Associated with Response to Therapy in Juvenile Idiopathic Arthritis"],"prefix":"10.3899","volume":"45","author":[{"given":"Faekah","family":"Gohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janneke","family":"Anink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Halima","family":"Moncrieffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisette W.A.","family":"Van Suijlekom-Smit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Femke H.M.","family":"Prince","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion A.J.","family":"van Rossum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koert M.","family":"Dolman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther P.A.H.","family":"Hoppenreijs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"ten Cate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simona","family":"Ursu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy R.","family":"Wedderburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Frosch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Foell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Holzinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"2018112909382929000_45.4.547.1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/nrrheum.2014.212","article-title":"Management of juvenile idiopathic arthritis: hitting the target","volume":"11","author":"Hinze","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"2018112909382929000_45.4.547.2","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20460"},{"key":"2018112909382929000_45.4.547.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.38092"},{"key":"2018112909382929000_45.4.547.4","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2003.014886"},{"key":"2018112909382929000_45.4.547.5","doi-asserted-by":"publisher","DOI":"10.1002\/art.23427"},{"key":"2018112909382929000_45.4.547.6","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.087411"},{"key":"2018112909382929000_45.4.547.7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1671"},{"key":"2018112909382929000_45.4.547.8","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket490"},{"key":"2018112909382929000_45.4.547.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2012.11.008"},{"key":"2018112909382929000_45.4.547.10","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200598"},{"key":"2018112909382929000_45.4.547.11","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1002\/acr.22248","article-title":"Validation of relapse risk biomarkers for routine use in patients with juvenile idiopathic arthritis","volume":"66","author":"Rothmund","year":"2013","journal-title":"Arthritis Care Res"},{"key":"2018112909382929000_45.4.547.12","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2010.375"},{"key":"2018112909382929000_45.4.547.13","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2012-201329"},{"key":"2018112909382929000_45.4.547.14","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket152"},{"key":"2018112909382929000_45.4.547.15","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s13075-015-0723-1","article-title":"MRP8\/14 serum levels as a predictor of response to starting and stopping anti-TNF treatment in juvenile idiopathic arthritis","volume":"17","author":"Anink","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2018112909382929000_45.4.547.16","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199707)40:7<1202::AID-ART3>3.0.CO;2-R"},{"key":"2018112909382929000_45.4.547.17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket470"},{"key":"2018112909382929000_45.4.547.18","doi-asserted-by":"publisher","DOI":"10.1002\/art.24516"},{"key":"2018112909382929000_45.4.547.19","doi-asserted-by":"publisher","DOI":"10.1002\/acr.20497"},{"key":"2018112909382929000_45.4.547.20","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.120842"},{"key":"2018112909382929000_45.4.547.21","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-200942"},{"key":"2018112909382929000_45.4.547.22","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.140651"},{"key":"2018112909382929000_45.4.547.23","doi-asserted-by":"crossref","first-page":"551","DOI":"10.3109\/14397595.2015.1109784","article-title":"Prediction of long-term remission of oligo\/polyarticular juvenile idiopathic arthritis with S100A12 and vascular endothelial growth factor","volume":"26","author":"Yamasaki","year":"2016","journal-title":"Mod Rheumatol"},{"key":"2018112909382929000_45.4.547.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/ket375"},{"key":"2018112909382929000_45.4.547.25","doi-asserted-by":"publisher","DOI":"10.1002\/art.10885"},{"key":"2018112909382929000_45.4.547.26","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203923"},{"key":"2018112909382929000_45.4.547.27","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-012-2146-6"},{"key":"2018112909382929000_45.4.547.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2010.02.026"},{"key":"2018112909382929000_45.4.547.29","unstructured":"CircuLex S100A12\/EN-RAGE ELISA Kit Ver.2. MBL Life Science [Internet. Accessed November 8, 2017.] Available from: http:\/\/ruo.mbl.co.jp\/bio\/g\/dtl\/P\/?pcd=CY-8058V2#u-pub"},{"issue":"Suppl 2","key":"2018112909382929000_45.4.547.30","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1136\/annrheumdis-2015-eular.4553","article-title":"Hexameric S100A12 is required for pro-inflammatory TLR4-signalling [abstract OP0194]","volume":"74","author":"Kessel","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"2018112909382929000_45.4.547.31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0060635"},{"key":"2018112909382929000_45.4.547.32","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.semarthrit.2015.02.003","article-title":"TNF-alpha gene polymorphisms and juvenile idiopathic arthritis: Influence on disease outcome and therapeutic response","volume":"45","author":"Scardapane","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2018112909382929000_45.4.547.33","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2010.143347"},{"key":"2018112909382929000_45.4.547.34","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.043299"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.170438","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,11,29]],"date-time":"2018-11-29T14:25:11Z","timestamp":1543501511000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.170438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":34,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4]]}},"alternative-id":["10.3899\/jrheum.170438"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.170438","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,15]]}}}